Sarcomas encompass a diverse group of heterogeneous tumors of mesenchymal cell origin that can be divided into malignancies containing either simple or complex genomic landscapes. Sarcomas with simple genomes often harbor a common genomic driver such as oncogenic fusion genes, while sarcomas with complex genomes exhibit chaotic karyotypes and extensive and largely non-recurrent genetic mutations. This complexity has complicated our understanding of the mechanisms underlying the tumorigenesis of sarcomas as well as the clinical approaches to their treatment. As the mutational landscape can promote drug resistance, enhance immune evasion, and reduce responses to immunotherapy, understanding the role of sarcoma genetics in shaping these processes is crucial to improving therapeutic outcomes in sarcoma patients.
The goal of this Research Topic is to report new perspectives and progress in our understanding of sarcoma pathobiology. Specifically, we aim to accelerate scientific communications in sarcoma research by exploring the contribution of the mutational landscape toward the tumor microenvironment, including impact on immune cell populations, metabolic reprogramming, and drug resistance. Revealing the molecular mechanisms that govern immune escape and tumor progression will significantly impact the development of novel therapeutic approaches targeting sarcoma cells and/or the tumor microenvironment.
We welcome the submission of Original Research and Review articles that address the link between the genomic landscape and the activation of molecular pathways in sarcoma cells, including interactions between tumor and non-malignant cells (e.g. fibroblasts, adipocytes, immune cells, and endothelial cells), that contribute to tumor progression, treatment resistance, and immunosuppression. Topics in the following areas are encouraged:
-The contribution of the mutational landscape to sarcoma progression and programming of the immune composition in the tumor microenvironment
-Signaling pathways related to drug resistance or immune evasion, and new strategies to overcome these obstacles
-Therapeutic strategies targeting the microenvironment and cellular interactions between sarcoma cells and the tumor stroma
-Contribution of genomic mutations to alterations in metabolism in sarcoma cells and impact of these metabolic changes on new and current treatment approaches and immunotherapy responses.
-Use or development of model systems for novel diagnostic and therapeutic approaches to unveil oncogenic mechanisms and to improve clinical outcomes of sarcoma patients.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Sarcomas encompass a diverse group of heterogeneous tumors of mesenchymal cell origin that can be divided into malignancies containing either simple or complex genomic landscapes. Sarcomas with simple genomes often harbor a common genomic driver such as oncogenic fusion genes, while sarcomas with complex genomes exhibit chaotic karyotypes and extensive and largely non-recurrent genetic mutations. This complexity has complicated our understanding of the mechanisms underlying the tumorigenesis of sarcomas as well as the clinical approaches to their treatment. As the mutational landscape can promote drug resistance, enhance immune evasion, and reduce responses to immunotherapy, understanding the role of sarcoma genetics in shaping these processes is crucial to improving therapeutic outcomes in sarcoma patients.
The goal of this Research Topic is to report new perspectives and progress in our understanding of sarcoma pathobiology. Specifically, we aim to accelerate scientific communications in sarcoma research by exploring the contribution of the mutational landscape toward the tumor microenvironment, including impact on immune cell populations, metabolic reprogramming, and drug resistance. Revealing the molecular mechanisms that govern immune escape and tumor progression will significantly impact the development of novel therapeutic approaches targeting sarcoma cells and/or the tumor microenvironment.
We welcome the submission of Original Research and Review articles that address the link between the genomic landscape and the activation of molecular pathways in sarcoma cells, including interactions between tumor and non-malignant cells (e.g. fibroblasts, adipocytes, immune cells, and endothelial cells), that contribute to tumor progression, treatment resistance, and immunosuppression. Topics in the following areas are encouraged:
-The contribution of the mutational landscape to sarcoma progression and programming of the immune composition in the tumor microenvironment
-Signaling pathways related to drug resistance or immune evasion, and new strategies to overcome these obstacles
-Therapeutic strategies targeting the microenvironment and cellular interactions between sarcoma cells and the tumor stroma
-Contribution of genomic mutations to alterations in metabolism in sarcoma cells and impact of these metabolic changes on new and current treatment approaches and immunotherapy responses.
-Use or development of model systems for novel diagnostic and therapeutic approaches to unveil oncogenic mechanisms and to improve clinical outcomes of sarcoma patients.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
